ExaGrid Wins “Storage Company of the Year” and “Vendor Channel Program of the Year” at 13th Annual 2022 SDC Awards
29.11.2022 16:00:00 EET | Business Wire | Press release
ExaGrid ®, the industry’s only Tiered Backup Storage solution, today announced that the company was honored with two awards at the 13th annual SDC Awards ceremony, Angel Business Communications’ premier IT awards – the Storage, Digitalisation + Cloud Awards, held in London on November 24, 2022. ExaGrid won “Storage Company of the Year” and “Vendor Channel Program of the Year,” making it the third year in a row for each. These new award wins add to ExaGrid’s previous four wins this past fall, totaling six industry awards in 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005098/en/
ExaGrid Wins “Storage Company of the Year” at 13th Annual 2022 SDC Awards (Photo: Business Wire)
ExaGrid’s Reseller Partner Program won “Vendor Channel Program of the Year.” ExaGrid offers one of the best deal registration programs in the industry to drive high margins along with deal SPIFFs and meeting maker bonuses. In addition, ExaGrid offers an optional Solutions Architects certification at no charge to become an ExaGrid Certified Solutions Architect. ExaGrid works with resellers and distributors worldwide and has customer installations in over 80 countries. The ExaGrid programs are designed to be easy for partners, with full support from the ExaGrid sales team - resulting in a 75% competitive win rate. ExaGrid is known for having a Tiered Backup Storage system that is highly differentiated and provides its customers with stellar customer support from an assigned level 2 engineer, ensuring that partners’ customers receive class “A” support.
ExaGrid also won “Storage Company of the Year” for the third year in a row. In 2021, ExaGrid expanded its product line with greater scalability up to 2.7PB full backup to a single system. In 2022, ExaGrid announced its Cloud Tier for Disaster Recovery in AWS and Azure as well as 30X faster Veeam synthetic fulls, improvements to its Retention Time-Lock features for ransomware recovery, and many other new features. ExaGrid has advanced IT tools and calculators to further assist a customer in calculating the true cost of backup storage up front and over time. These tools show customers what their costs of backup storage will be - inclusive of backup rotation, backup retention, yearly data growth, and second site disaster recovery.
ExaGrid has had back-to-back record quarters in 2022 and has expanded its customer base to over 3,600 customers in over 80 countries. ExaGrid continues to be cash positive, EBITDA positive, and P&L positive quarter after quarter. ExaGrid is the only company that is completely dedicated to backup storage, with a goal to solve the issues commonly experienced with backup solutions while providing the best value to its customers, including the fastest backups, fastest restores, a fixed length backup window as data grows, comprehensive security including ransomware recovery and low cost up front and overtime.
“These two awards simply say it all. We apply 100% of our focus on serving our channel partners with our Tiered Backup Storage offering,” said Bill Andrews, President and CEO of ExaGrid. “Congratulations to all the 2022 winners! We are certainly in good company. Since these awards are voted on by the public, it means a great deal to us. We will continue to push the limits with our Tiered Backup Storage solution and expert-level support.”
ExaGrid continues to gain recognition for its Tiered Backup Storage appliances, winning six awards in 2022, which is the most for any backup storage provider in 2022, including:
- SDC Awards – Storage Company of the Year
- SDC Awards – Vendor Channel Program of the Year
- Storage Awards – Enterprise Backup Hardware Vendor of the Year
- Network Computing Awards – Bench Tested Product of the Year
- Network Computing Awards – Company of the Year
- Network Computing Awards – Storage Product of the Year
This is the 3rd year in a row that ExaGrid won more backup storage provider awards than any other vendor.
ExaGrid Tiered Backup Storage
ExaGrid provides Tiered Backup Storage with a front-end disk-cache Landing Zone, which writes data directly to disk for the fastest backups and restores directly from disk for the fastest restores and VM boots. The long-term retention data is tiered to a deduplicated data repository, the Retention Tier, to reduce the amount of retention storage and resulting cost. This two-tiered approach provides the fastest backup and restore performance with the lowest cost storage efficiency.
In addition, ExaGrid provides a scale-out architecture where appliances are simply added as data grows. Each appliance includes processor, memory, and network ports, so as data grows, all resources required are available to maintain a fixed-length backup window. This scale-out storage approach eliminates expensive forklift upgrades and allows for mixing appliances of different sizes and models in the same scale-out system, which eliminates product obsolescence while protecting IT investments up front and over time.
About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks.
ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, Iberia, India, Israel, Japan, Mexico, Nordics, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.
Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup in our customer success stories . Check out our 100+ Gartner Peer Insight Reviews . ExaGrid is proud of our +81 NPS score.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005098/en/
Contact information
Media:
Mary Domenichelli
ExaGrid
mdomenichelli@exagrid.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
